Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonist
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16047 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Amina Z Haggag und 21 weiteren Autor:innen. Beteiligte Einrichtung: Anaheim Clinical Trials LLC, Anaheim, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents, Small Molecule Libraries. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eccogene and AstraZeneca.
Abstract (Originalsprache)
Aims
GLP‐1 receptor agonists (GLP‐1 RAs) are proven therapies for type 2 diabetes mellitus (T2DM) and overweight or obesity. We performed non‐clinical and first‐in‐human (FIH) evaluation of ECC5004/AZD5004, an oral small‐molecule GLP‐1 RA. Materials and Methods ECC5004 was profiled in cell lines overexpressing human GLP‐1R, in glucose‐stimulated insulin secretion (GSIS) assays in a human β‐cell line and non‐human primates (NHPs). To evaluate safety, ECC5004 was orally administered to NHPs for 9 months and a phase I, double‐blind, placebo‐controlled FIH study was conducted. This study evaluated single doses of ECC5004 (1–300 mg) in healthy volunteers, and multiple daily doses (5, 10, 30 and 50 mg) in patients with T2DM for 28 days.
Results
ECC5004 bound to the hGLP‐1R (IC 50 = 2.4 nM) augmented cAMP signalling without β‐arrestin‐2 recruitment or receptor internalization. ECC5004 potentiated GSIS in both EndoC‐βH5 cells (EC 50 = 5.9 nM) and in vivo in NHPs (EC 50 = 0.022 nM). Dose‐dependent body weight changes compared to control were seen in the 9‐month NHP toxicity study. In the first‐in‐human study, ECC5004 was well tolerated with no serious adverse events. Dose‐dependent reductions in glucose and body weight were observed with a dose‐proportional exposure at doses ≥25 mg.
Conclusion
ECC5004 engaged the GLP‐1R across the therapeutic dose range tested and had a safety and tolerability profile consistent with other GLP‐1 RAs, along with a pharmacokinetic profile compatible with once‐daily oral dosing. These data support continued development of ECC5004 as a potential therapy for T2DM and overweight or obesity. Clinical trial registration : NCT05654831.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anaheim Clinical Trials LLC, Anaheim, California, USA.
- Eccogene Inc., Cambridge, Massachusetts, USA.
- QPS MRA LLC, Miami, Florida, USA.
- Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Assays, Profiling and Cell Sciences, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
ORCID-Profile: Jingye Zhou
Förderung
- Eccogene and AstraZeneca
Zitieren
APA
Haggag, A. Z., Xu, J., Butcher, L., Pagnussat, S., Davies, G., Lundqvist, S., Wang, W., Van Zuydam, N., Nelander, K., Jha, A., Yu, H., Boianelli, A., Lindmark, B., Ollerstam, A., Sun, X., Wang, F., Pan, X., Liu, H., Chen, W., …, & Zhou, J. (2025). Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonist. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16047
Vancouver
Haggag AZ, Xu J, Butcher L, Pagnussat S, Davies G, Lundqvist S, et al. Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonist. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16047
BibTeX
@article{Haggag2025,
author = {Haggag, Amina Z and Xu, Jianfeng and Butcher, Laurie and Pagnussat, Sandra and Davies, Graeme and Lundqvist, Sara and Wang, Wenyu and Van Zuydam, Natalie and Nelander, Karin and Jha, Aruni and Yu, Hongtao and Boianelli, Alessandro and Lindmark, Bosse and Ollerstam, Anna and Sun, Xuefeng and Wang, Fan and Pan, Xiaoliang and Liu, Haihui and Chen, Wengang and Xu, Jianfeng and Wallenius, Kristina and Zhou, Jingye},
title = {Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonist},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16047}
}
EUVIMED